science
Regenxbio Gene Therapy for Duchenne Muscular Dystrophy Succeeds in Trial
Regenxbio announced on May 14, 2026 that its experimental treatment produced high levels of a miniaturized muscle protein, clearing the path for an FDA submission. The Rockville, Md.-based company aims to offer a safer and more effective option than Sarepta Therapeutics’ Elevidys, which has been linked to two deaths from liver failure.
May 14, 7:00 AM·1m read1 source
StatAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Regenxbio announced on May 14, 2026 that its experimental gene therapy for Duchenne muscular dystrophy produced sufficiently high levels of a miniaturized muscle protein broken in the fatal neuromuscular disease. The announcement, made on Thursday, May 14, 2026, paves the way for a submission to the Food and Drug Administration.
, is seeking to create a Duchenne gene therapy that is more effective and safer than Sarepta Therapeutics’ Elevidys.
Elevidys has been hampered by safety concerns, particularly following the deaths of two recipients from liver failure. “I think our data checks every single box that you would want for accelerated approval,” Regenxbio CEO Curran Simpson told STAT. Curran Simpson leads the company as it moves toward regulatory filing after the positive clinical trial results.
The gene therapy’s performance on the key muscle protein marker positions Regenxbio to pursue accelerated approval from the FDA. Adam Feuerstein and Jason Mast wrote the article published by STAT on May 14, 2026. Adam Feuerstein is a senior writer and biotech columnist at STAT, co-host of The Readout Loud podcast, and author of Adam’s Biotech Scorecard.
Stat reported the full details of the trial success and Regenxbio’s competitive positioning against the existing approved therapy. , served as the base for the development effort now entering its next regulatory phase. Regenxbio’s announcement marks a concrete step forward in treating the fatal neuromuscular disease by addressing both efficacy and safety shortcomings observed with the prior treatment.
